TITLE

Zydus Cadila forms joint venture with Germany's Bayer Healthcare

PUB. DATE
February 2011
SOURCE
Chemical Business;Feb2011, Vol. 25 Issue 2, p59
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of drug manufacturer Zydus Cadila to form a 50:50 joint venture with German firm Bayer Healthcare to sell pharmaceutical products in India in 2011.
ACCESSION #
59414645

 

Related Articles

  • Zydus Cadila gets US nod for anti-depressant drug.  // FRPT- Chemical Snapshot;2/9/2014, p17 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the Bupropion Hydrochloride extended-release tablets, an anti-depressant drug, from pharamaceutical company Zydus Cadila.

  • Zydus receives final approval from the USFDA for Acetazolamide for Injection.  // FRPT- Chemical Snapshot;4/30/2019, p19 

    The article informs that pharmaceutical company Zydus Cadila has received the final approval from the U.S. regulator Food and Drug Authority to market Acetazolamide for Injection USP (US RLD Diamox for Injection), 500 mg per single-dose vial.

  • SEZs in Gujarat post robust growth in 2016-17.  // FRPT- Chemical Snapshot;4/4/2017, p20 

    The article presents a report on growth in Special Economic Zones in Gujarat, India and mentions the views of Upendra Vasishth, Zonal Development Commissioner, Gujarat, on high growth in Zydus Cadila on the basis of value of exports.

  • Zydus planning biologics push in next two years.  // FRPT- Chemical Snapshot;10/19/2014, p21 

    The article reports on the plan of pharmaceutical company Zydus Cadila Healthcare Ltd. to launch three biologic products in 2015 and to have a portfolio of 15 products in 2016 in India. The research and investment of Zydus for the manufacture biosimilars are discussed. Also noted is the alliance...

  • MUTED RESPONSE. PANDEY, KUNDAN // Down to Earth;1/16/2014, Vol. 22 Issue 17, p38 

    The article discusses the initiative launched by the government of Meghalaya, India to deal with Hepatitis C Virus (HCV). It states that the government assured treatment to people co-infected with HIV and HCV. It mentions that the government bought the HCV treatment form Indian pharmaceutical...

  • GPCB issues closure notice to Zydus Cadila research unit.  // FRPT- Chemical Snapshot;3/16/2014, p15 

    The article reports on a closure notice issued by Gujarat Pollution Control Board (GPCB) of India to global pharmaceutical company Zydus Cadila's research unit in Ahmedabad for allegedly polluting ground water in the area. Topics discussed include a statement from GPCB regional officer Anil...

  • Zydus Cadila, SIFI tie up to launch innovative intraocular lenses in India.  // Ace Analyser: Company News;4/30/2019, pN.PAG 

    Zydus Cadila and SIFI look forward to bringing such innovations to India and to the entire South Asia region

  • Zydus Cadila completes enrolment in Evidences IV phase 2 clinical trial of Saroglitazar Magnesium.  // Ace Analyser: Company News;6/17/2019, pN.PAG 

    The trial will evaluate the percentage change from baseline in serum ALT levels in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint

  • Zydus Cadila gets USFDA's nod for Bosentan Tablets, Trientine Hydrochloride Capsules.  // Ace Analyser: Company News;4/30/2019, pN.PAG 

    Both the products will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics